VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Ku on Immunotherapy in Gastric and Esophageal Cancer

Geoffrey Y. Ku, MD
Published: Thursday, Feb 09, 2017



Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center discusses immunotherapy treatments for patients with gastric and esophageal cancers.

Researchers of a phase III study tested almost 500 patients who had previously received 2 or more chemotherapy treatments. These patients were treated with either nivolumab (Opdivo), the PD-1 antibody, or placebo.

There was a 12-month overall survival rate of 27% in these patients versus the 11% in patients who had received placebo. For the first time, this phase III evidence confirmed that these drugs are active in patients with gastric and esophageal cancers, says Ku.



Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center discusses immunotherapy treatments for patients with gastric and esophageal cancers.

Researchers of a phase III study tested almost 500 patients who had previously received 2 or more chemotherapy treatments. These patients were treated with either nivolumab (Opdivo), the PD-1 antibody, or placebo.

There was a 12-month overall survival rate of 27% in these patients versus the 11% in patients who had received placebo. For the first time, this phase III evidence confirmed that these drugs are active in patients with gastric and esophageal cancers, says Ku.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x